| CAS NO: | 320725-47-1 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| Cas No. | 320725-47-1 |
| 别名 | MSI-1256F |
| Canonical SMILES | NCCCCNCCCN[C@H]1CC[C@@]2(C)[C@](C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CC[C@@H](OS(=O)(O)=O)C(C)C)([H])C1.C[C@@H](C(O)=O)O |
| 分子式 | C37H71N3O8S |
| 分子量 | 718.04 |
| 溶解度 | DMSO : ≥ 36.66 mg/mL (51.06 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration. Squalamine lactate has a more generalized effect on the cellular signaling cascade that is common to both VEGF and other growth factors[1]. Squalamine blocks the action of VEGF and integrin expression, thereby inhibiting angiogenesis, when bound to calmodulin[2]. Squalamine is ineffective when administered intravitreally and therefore requires intravenous dosing. However, systemic dosing has yielded promising results in rats as well as humans[2]. [1]. Hussain RM, et al. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246. [2]. Emerson MV, et al. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008 Jun;2(2):377-88. |
m.cnreagent.com